Jiade reports H1 2026 net loss of RMB 50.5m as stock compensation lifts costs
Jiade Limited's unaudited half-year accounts show revenue slipping to RMB 8.3m while general and administrative spending climbed to RMB 48.8m, including about RMB 33m of share-based pay.
Jiade Limited has published unaudited condensed financial statements for the six months ended 30 June 2026, showing a net loss of RMB 50.5m. Revenue fell to RMB 8.3m, down from RMB 9.4m in the comparable period.
The main driver of the loss was general and administrative expenses, which rose to RMB 48.8m. About RMB 33m of that figure was stock-based compensation, meaning roughly two-thirds of the administrative cost base was a non-cash share-related charge.
On the balance sheet, the company raised about RMB 96m through the issue of Class A shares. Cash rose to RMB 51.8m, while intangible assets increased to RMB 107m.
The release does not name any product, indication or regulator, so it gives no indication of how the financial figures relate to any development, licensing or regulatory activity. The statements are unaudited.
Why it matters
- The release contains no product, indication or regulatory information, so it offers no direct signal for regulatory, pharmacovigilance or quality teams.
- Market-access and partnering teams assessing Jiade as a counterparty may note the small revenue base, the loss and the recent equity raise, which lifted cash to RMB 51.8m.
- The figures are unaudited and the release does not explain what the intangible assets of RMB 107m comprise.
Company's press release (SEC filing): JIADE Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
